-
公开(公告)号：US20190328698A1
公开(公告)日：2019-10-31
申请号：US16460208
申请日：2019-07-02
发明人： Annabelle Gallois-Bernos , Frank F. Molock, JR. , Carrie L. Davis , Kathrine Osborn Lorenz , James K. Young , Kristy L. Canavan , Fang Lu
IPC分类号： A61K31/232 , A61K31/203 , A61K31/16 , A61K31/201 , A61K31/202 , A61K31/557 , A61K9/00 , A61K31/661 , A61K31/5575 , A61K31/215 , A61K31/683
摘要： The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a monohydric alcohol or an amide wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens.
-
公开(公告)号：US20200222357A1
公开(公告)日：2020-07-16
申请号：US16831011
申请日：2020-03-26
发明人： Annabelle Gallois-Bernos , Frank F. Molock, JR. , Carrie L. Davis , Kathrine Osborn Lorenz , James K. Young , Kristy L. Canavan , Fang Lu
IPC分类号： A61K31/232 , A61K31/215 , A61K31/683 , A61K31/203 , A61K31/201 , A61K9/00 , A61K31/557 , A61K31/202 , A61K31/16 , A61K31/661 , A61K31/5575
摘要： The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a monohydric alcohol or an amide wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. Anti-inflammatory lipid mediators can be selected from the group consisting of polyunsaturated fatty acids (e.g., omega-three and omega-six fatty acids), resolvins or a metabolically stable analog, protectins or a metabolically stable analog, lipoxins or a metabolically stable analog, prostaglandins or a metabolically stable analog, retinoic acids, endocannabinoids, metabolites thereof, and mixtures thereof. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens.
-
公开(公告)号：US09849081B2
公开(公告)日：2017-12-26
申请号：US15434114
申请日：2017-02-16
IPC分类号： A61K31/785 , A61K31/74 , G02B1/04 , A61K9/00 , A61K31/765 , A61K31/78 , C11D3/00
CPC分类号： A61K9/0048 , A61K31/765 , A61K31/78 , C11D3/0078 , G02B1/041 , G02B1/043 , C08L33/12
摘要： The present invention relates to ophthalmic solutions and devices comprising at least one water soluble polymer having a molecular weight of at least about 500,000 Daltons and comprising linear or branched polyether pendant groups having a molecular weight of at least about 300.
-
公开(公告)号：US09606263B2
公开(公告)日：2017-03-28
申请号：US15335569
申请日：2016-10-27
IPC分类号： A61K31/785 , A61K31/74 , G02B1/04
CPC分类号： A61K9/0048 , A61K31/765 , A61K31/78 , C11D3/0078 , G02B1/041 , G02B1/043 , C08L33/12
摘要： The present invention relates to ophthalmic solutions and devices comprising at least one water soluble polymer having a molecular weight of at least about 500,000 Daltons and comprising linear or branched polyether pendant groups having a molecular weight of at least about 300.
-
公开(公告)号：US20170157037A1
公开(公告)日：2017-06-08
申请号：US15434114
申请日：2017-02-16
IPC分类号： A61K9/00 , G02B1/04 , C11D3/00 , A61K31/765 , A61K31/78
CPC分类号： A61K9/0048 , A61K31/765 , A61K31/78 , C11D3/0078 , G02B1/041 , G02B1/043 , C08L33/12
摘要： The present invention relates to ophthalmic solutions and devices comprising at least one water soluble polymer having a molecular weight of at least about 500,000 Daltons and comprising linear or branched polyether pendant groups having a molecular weight of at least about 300.
-
公开(公告)号：US20170042933A1
公开(公告)日：2017-02-16
申请号：US15335569
申请日：2016-10-27
IPC分类号： A61K31/78 , G02B1/04 , C08F220/28 , A61K31/765 , A61K9/00
CPC分类号： A61K9/0048 , A61K31/765 , A61K31/78 , C11D3/0078 , G02B1/041 , G02B1/043 , C08L33/12
摘要： The present invention relates to ophthalmic solutions and devices comprising at least one water soluble polymer having a molecular weight of at least about 500,000 Daltons and comprising linear or branched polyether pendant groups having a molecular weight of at least about 300.
摘要翻译： 本发明涉及眼用溶液和装置，其包含至少一种分子量至少为约500,000道尔顿的水溶性聚合物，并且包含分子量至少为约300的直链或支链聚醚侧基。
-
公开(公告)号：US20210379005A1
公开(公告)日：2021-12-09
申请号：US17445520
申请日：2021-08-20
发明人： Annabelle Gallois-Bernos , Frank F. Molock, JR. , Carrie L. Davis , Kathrine Osborn Lorenz , James K. Young , Kristy L. Canavan , Fang Lu
IPC分类号： A61K31/232 , A61K31/557 , A61K31/215 , A61K31/5575 , A61K31/661 , A61K9/00 , A61K31/16 , A61K31/201 , A61K31/202 , A61K31/203 , A61K31/683
摘要： The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a monohydric alcohol or an amide wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. Anti-inflammatory lipid mediators can be selected from the group consisting of polyunsaturated fatty acids (e.g., omega-three and omega-six fatty acids), resolvins or a metabolically stable analog, protectins or a metabolically stable analog, lipoxins or a metabolically stable analog, prostaglandins or a metabolically stable analog, retinoic acids, endocannabinoids, metabolites thereof, and mixtures thereof. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens.
-
公开(公告)号：US11096919B2
公开(公告)日：2021-08-24
申请号：US16460208
申请日：2019-07-02
发明人： Annabelle Gallois-Bernos , Frank F. Molock, Jr. , Carrie L. Davis , Kathrine Osborn Lorenz , James K. Young , Kristy L. Canavan , Fang Lu
IPC分类号： A61K31/232 , A61K31/557 , A61K31/215 , A61K31/5575 , A61K31/661 , A61K9/00 , A61K31/16 , A61K31/201 , A61K31/202 , A61K31/203 , A61K31/683 , A61K9/08
摘要： The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a monohydric alcohol or an amide wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens.
-
公开(公告)号：US10441533B2
公开(公告)日：2019-10-15
申请号：US15811760
申请日：2017-11-14
IPC分类号： A61K9/00 , G02B1/04 , A61K31/765 , A61K31/78 , C11D3/00
摘要： The present invention relates to ophthalmic solutions and devices comprising at least one water soluble polymer having a molecular weight of at least about 500,000 Daltons and comprising linear or branched polyether pendant groups having a molecular weight of at least about 300.
-
公开(公告)号：US20180064642A1
公开(公告)日：2018-03-08
申请号：US15811760
申请日：2017-11-14
IPC分类号： A61K9/00 , G02B1/04 , C11D3/00 , A61K31/765 , A61K31/78
CPC分类号： A61K9/0048 , A61K31/765 , A61K31/78 , C11D3/0078 , G02B1/041 , G02B1/043 , C08L33/12
摘要： The present invention relates to ophthalmic solutions and devices comprising at least one water soluble polymer having a molecular weight of at least about 500,000 Daltons and comprising linear or branched polyether pendant groups having a molecular weight of at least about 300.
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.019 秒)
